- •Tethering can provide a novel way for spatiotemporal control of drug delivery.
- •Use of in vivo vitiligo models is a proof of concept for the therapeutic efficacy of tethering.
- •Tethering of biologics has a potential for treatment of other autoimmune diseases.
Anchoring as a novel method to target a drug to a specific location
Potential clinical implications for vitiligo
Potential implications for other autoimmune diseases
Conflicts of Interest
- Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection.Proc Natl Acad Sci USA. 1985; 82: 7404-7408
- Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.Immunity. 1994; 1: 447-456
- A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin.J Invest Dermatol. 2012; 132: 1869-1876
- Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus mAb.J Invest Dermatol. 2013; 133: 2212-2220
- Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display.J Clin Invest. 2005; 115: 888-899
- CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.Sci Transl Med. 2014; 6: 223ra23
- Understanding the targeting mechanisms of multi-specific biologics in immunotherapy with multiscale modeling.iScience. 2020; 23101835
- A keratinocyte-tethered biologic enables location-precise treatment in mouse vitiligo.J Invest Dermatol. 2022; 142: 3294-3303
See related article on pg 3294